RT Journal Article SR Electronic T1 Influence of vaccine prevention of pneumoccocus conjugated vaccine on mortality in patients with COPD JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP 2425 DO 10.1183/13993003.congress-2020.2425 VO 56 IS suppl 64 A1 Vladimir Antonov A1 Galina Ignatova YR 2020 UL http://erj.ersjournals.com/content/56/suppl_64/2425.abstract AB Objective: to analyze the effectiveness of vaccine prophylaxis 13-valence conjugated pneumococcal vaccine (PCV13) by the effect on mortality in COPD patients.Material and Methods: 362 male patients with COPD: group 1 - 150 patients vaccinated with PCV13, group 2 - 212 people unvaccinated. The observation period is 7 years. The average age of the studied groups was 68.56 (95% CI; 62.46-74.27) years. Mortality per 1000 vaccinated / unvaccinated was calculated patients. The structure of mortality in the age groups under 65 years old and over 65 is analyzed years. For vaccine prophylaxis, 13-valent conjugated vaccine pneumococcal was used.Results: patients in both groups were statistically comparable: up to 65 years old - 31% in the first group and 32% in the second, over 65 years old - 69% in the group PCV13 and 68% in the group of unvaccinated. During the observation period among vaccinated was 6 deaths were registered, mortality rate - 39.9. In the group of unvaccinated patients there were 17 deaths, the mortality rate was 80.2, which is statistically significantly higher in comparison with the 1st group. Cardiovascular diseases (40%) and COPD progression (47%) predominated in the mortality structure, especially in unvaccinated patients older than 65 years (p<0.05).Conclusions: 1. An increase in age is associated with an increase in mortality, regardless of vaccine prophylaxis. 2. The main causes of mortality in both observation groups are cardiovascular disease and the progression of COPD however level the mortality rate in the unvaccinated group is significantly higher. 3. The use of PCV13 vaccination significantly reduces mortality, especially due to COPD.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 2425.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).